Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bruzzi

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patientsAlberto Bottini, Daniele Generali, Maria Pia Brizzi, et al.
Scientific Reports|January 23, 2016
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancerCecilia Marini, Giovanna Bianchi, Ambra Buschiazzo, et al.
Breast Cancer Research and Treatment|December 15, 2015
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trialLucia Del Mastro, Alessia Levaggi, Andrea Michelotti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
Cancer|October 13, 2005
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantationJacopo Peccatori, Lisbeth Barkholt, Tanner Demirer, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2013
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinibMarcello Tiseo, Massimo Ippolito, Maura Scarlattei, et al.
Annals of Surgical Oncology|May 13, 2022
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical TrialCorrado Tinterri, Damiano Gentile, Wolfgang Gatzemeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplificationBruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trialBernardo Bonanni, Matteo Puntoni, Massimiliano Cazzaniga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2013
Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma GroupAlessandro Gronchi, Antonino De Paoli, Carla Dani, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patientsAlberto Bottini, Daniele Generali, Maria Pia Brizzi, et al.
Scientific Reports|January 23, 2016
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancerCecilia Marini, Giovanna Bianchi, Ambra Buschiazzo, et al.
Breast Cancer Research and Treatment|December 15, 2015
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trialLucia Del Mastro, Alessia Levaggi, Andrea Michelotti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2009
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursVanesa Gregorc, Giovanni Citterio, Giordano Vitali, et al.
Cancer|October 13, 2005
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantationJacopo Peccatori, Lisbeth Barkholt, Tanner Demirer, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2013
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinibMarcello Tiseo, Massimo Ippolito, Maura Scarlattei, et al.
Annals of Surgical Oncology|May 13, 2022
Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical TrialCorrado Tinterri, Damiano Gentile, Wolfgang Gatzemeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplificationBruno De Bernardi, Mary Gerrard, Luca Boni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trialBernardo Bonanni, Matteo Puntoni, Massimiliano Cazzaniga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2013
Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma GroupAlessandro Gronchi, Antonino De Paoli, Carla Dani, et al.
Pageof 16